ATE527253T1 - Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer - Google Patents
Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmerInfo
- Publication number
- ATE527253T1 ATE527253T1 AT06774386T AT06774386T ATE527253T1 AT E527253 T1 ATE527253 T1 AT E527253T1 AT 06774386 T AT06774386 T AT 06774386T AT 06774386 T AT06774386 T AT 06774386T AT E527253 T1 ATE527253 T1 AT E527253T1
- Authority
- AT
- Austria
- Prior art keywords
- pyrimidine
- protein kinase
- kinase inhibitors
- benzimidazole derivatives
- substituted benzimidazole
- Prior art date
Links
- -1 PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE Chemical class 0.000 title 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 102000001332 SRC Human genes 0.000 abstract 1
- 108060006706 SRC Proteins 0.000 abstract 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69617405P | 2005-07-01 | 2005-07-01 | |
| PCT/US2006/025706 WO2007005673A1 (en) | 2005-07-01 | 2006-06-30 | Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE527253T1 true ATE527253T1 (de) | 2011-10-15 |
Family
ID=37110309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06774386T ATE527253T1 (de) | 2005-07-01 | 2006-06-30 | Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8426404B2 (https=) |
| EP (1) | EP1899329B1 (https=) |
| JP (1) | JP5054004B2 (https=) |
| KR (1) | KR20080015475A (https=) |
| CN (1) | CN101213192B (https=) |
| AT (1) | ATE527253T1 (https=) |
| AU (1) | AU2006265840B2 (https=) |
| BR (1) | BRPI0613501A2 (https=) |
| CA (1) | CA2614148A1 (https=) |
| ES (1) | ES2375151T3 (https=) |
| MX (1) | MX2007016066A (https=) |
| PL (1) | PL1899329T3 (https=) |
| PT (1) | PT1899329E (https=) |
| RU (1) | RU2386630C2 (https=) |
| WO (1) | WO2007005673A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| US7132426B2 (en) | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| MX2009002046A (es) | 2006-08-24 | 2009-03-06 | Astrazeneca Ab | Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos. |
| WO2008153701A1 (en) * | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| CN101809002B (zh) | 2007-07-09 | 2013-03-27 | 阿斯利康(瑞典)有限公司 | 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物 |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EP2307456B1 (en) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| PA8851101A1 (es) * | 2008-12-16 | 2010-07-27 | Lilly Co Eli | Compuesto amino pirazol |
| AU2010216239B2 (en) * | 2009-02-18 | 2012-06-14 | Amgen Inc. | Indole/benzimidazole compounds as mTOR kinase inhibitors |
| WO2010100127A1 (en) * | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
| SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| CN102947274A (zh) * | 2010-06-17 | 2013-02-27 | 诺瓦提斯公司 | 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物 |
| PH12013500547A1 (en) | 2010-09-22 | 2013-06-10 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| US9061028B2 (en) | 2012-02-15 | 2015-06-23 | Natco Pharma Limited | Process for the preparation of Nilotinib |
| US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
| KR101469127B1 (ko) * | 2013-03-11 | 2014-12-04 | 한양대학교 에리카산학협력단 | 신규 벤즈이미다졸 유도체, 이의 이성질체 또는 이의 약학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| AU2015292818B2 (en) * | 2014-07-21 | 2020-01-16 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| KR101850282B1 (ko) * | 2014-11-26 | 2018-05-31 | 한국과학기술연구원 | 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체 |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| EP3939965A1 (en) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| WO2017066193A1 (en) | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Novel inhibitors of protein kinases |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| KR101840674B1 (ko) | 2017-02-20 | 2018-03-21 | 한양대학교 에리카산학협력단 | Jnk 저해 활성을 갖는 신규한 벤즈이미다졸 유도체 및 이의 용도 |
| US20200377505A1 (en) * | 2017-08-04 | 2020-12-03 | Goldfinch Bio., Inc. | Benzimidazoles and aza-benzimidazoles, and methods of use thereof |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| KR20230084416A (ko) * | 2021-12-03 | 2023-06-13 | 연세대학교 산학협력단 | Wnk3 억제제를 유효성분으로 포함하는 면역관문 억제용 조성물 |
| KR20250130162A (ko) * | 2024-04-17 | 2025-09-01 | 한양대학교 에리카산학협력단 | 단백질 인산화 효소 저해 활성을 갖는 신규한 벤조이미다졸 유도체 및 이의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1243002C (zh) * | 1998-11-17 | 2006-02-22 | 组合化学工业株式会社 | 嘧啶基苯并咪唑和三嗪基苯并咪唑衍生物及农业/园艺杀菌剂 |
| EP1257546A1 (en) * | 2000-02-17 | 2002-11-20 | Amgen Inc. | Kinase inhibitors |
| EP1389617B1 (en) * | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
-
2006
- 2006-06-30 PL PL06774386T patent/PL1899329T3/pl unknown
- 2006-06-30 KR KR1020077030728A patent/KR20080015475A/ko not_active Abandoned
- 2006-06-30 RU RU2008103143/04A patent/RU2386630C2/ru not_active IP Right Cessation
- 2006-06-30 PT PT06774386T patent/PT1899329E/pt unknown
- 2006-06-30 US US11/915,148 patent/US8426404B2/en not_active Expired - Fee Related
- 2006-06-30 CN CN2006800242273A patent/CN101213192B/zh not_active Expired - Fee Related
- 2006-06-30 WO PCT/US2006/025706 patent/WO2007005673A1/en not_active Ceased
- 2006-06-30 MX MX2007016066A patent/MX2007016066A/es not_active Application Discontinuation
- 2006-06-30 JP JP2008519635A patent/JP5054004B2/ja not_active Expired - Fee Related
- 2006-06-30 AT AT06774386T patent/ATE527253T1/de active
- 2006-06-30 AU AU2006265840A patent/AU2006265840B2/en not_active Expired - Fee Related
- 2006-06-30 BR BRPI0613501-3A patent/BRPI0613501A2/pt not_active IP Right Cessation
- 2006-06-30 EP EP06774386A patent/EP1899329B1/en not_active Not-in-force
- 2006-06-30 CA CA002614148A patent/CA2614148A1/en not_active Abandoned
- 2006-06-30 ES ES06774386T patent/ES2375151T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1899329B1 (en) | 2011-10-05 |
| AU2006265840A1 (en) | 2007-01-11 |
| JP2009500348A (ja) | 2009-01-08 |
| US20080255112A1 (en) | 2008-10-16 |
| WO2007005673A1 (en) | 2007-01-11 |
| PL1899329T3 (pl) | 2012-03-30 |
| PT1899329E (pt) | 2012-01-13 |
| RU2008103143A (ru) | 2009-08-10 |
| JP5054004B2 (ja) | 2012-10-24 |
| CN101213192B (zh) | 2012-06-06 |
| CA2614148A1 (en) | 2007-01-11 |
| RU2386630C2 (ru) | 2010-04-20 |
| AU2006265840B2 (en) | 2010-02-11 |
| KR20080015475A (ko) | 2008-02-19 |
| ES2375151T3 (es) | 2012-02-27 |
| CN101213192A (zh) | 2008-07-02 |
| BRPI0613501A2 (pt) | 2011-01-11 |
| EP1899329A1 (en) | 2008-03-19 |
| US8426404B2 (en) | 2013-04-23 |
| MX2007016066A (es) | 2008-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE527253T1 (de) | Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer | |
| EA200970156A1 (ru) | Пиридизиноновые производные | |
| CY1114539T1 (el) | Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων | |
| EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
| NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
| NO20090295L (no) | Substituerte heteroarylderivater | |
| EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| ATE479687T1 (de) | Kinaseinhibitoren | |
| MX2009011964A (es) | Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico. | |
| NO20070529L (no) | Kinazolindionderivater som parp-inhibitorer | |
| ATE469151T1 (de) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
| WO2006123113A3 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
| DE60309848D1 (de) | Purinderivate als kinaseinhibitoren | |
| ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
| CY1112828T1 (el) | Ενωσεις αναστολης της μιτωτικης διαδικασιας | |
| NO20081636L (no) | FAP - inhibitorer | |
| NO20065148L (no) | Monocykliske heterocykler som kinase inhibitorer | |
| ATE554087T1 (de) | Neue kinaseinhibitoren | |
| EA200800240A1 (ru) | Производные тиазола в качестве активатора амфк | |
| NI201000059A (es) | Inhibidores de la cinasa c-fms. | |
| EA200700168A1 (ru) | Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы | |
| EA200900135A1 (ru) | Производные пиразола в качестве ингибиторов цитохрома р450 | |
| UY30297A1 (es) | Inhibidores de la quinasa c-fms-i | |
| NO20090738L (no) | Tilveiebringelse av EP2 agonister, fremgangsmate for fremstilling derav, farmasoytiske sammensetninger inneholdende disse forbindelser og fremgangsmater for anvendelse av forbindelsene og sammensetningene for a senke intraokkulaert trykk og behandle glaukom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1899329 Country of ref document: EP |